2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

Innovent Biologics Presentation: Innovent Biologics announced the presentation of preclinical data on novel bispecific and tri-specific antibodies, as well as bispecific antibody-drug conjugates (ADCs), at the AACR Annual Meeting 2025, showcasing advancements in their oncology pipeline aimed at treating difficult-to-treat cancers.

Research Highlights: Key research findings include IAR037, a bispecific antibody for immune checkpoint inhibitor-resistant tumors, and IBI3010, an ADC targeting FRα expressing tumors, both demonstrating promising efficacy and safety profiles in preclinical studies.